The CLL17 trial showed noninferiority of fixed-duration regimens compared to continuous BTK inhibitor therapy, highlighting ...

Antigen spreading was evaluated in a subset of Phase 2 patients to assess the ability of ELI-002 7P to broaden immune responses to personalized tumor neoantigens not present in the targeted ...

Done right, video depositions can be powerful evidence, locking in key admissions or juicy details. Videotaped depositions are much more than just perfunctory stepping stones on your path through the ...

SITC abstracts highlight updated immunogenicity results from the Phase 2 AMPLIFY-7P trial of ELI-002 7P and preclinical data on the use of intratumoral ELI-004 (AMP-CpG) for solid tumor immunotherapy ...

Recent developments in the treatment of chronic lymphocytic leukemia (CLL) have included a fixed-duration oral combination regimen for untreated patients and promising results with a Bruton's tyrosine ...

BOSTON, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies ...

AbbVie seeks FDA approval for Venclexta and Calquence combination for untreated CLL, following positive AMPLIFY trial results. The combination regimen showed a 35% reduction in disease progression or ...

Combination therapy has potential to be an all-oral, fixed-duration regimen for previously untreated patients with CLL Application is supported by data from the Phase 3 AMPLIFY trial that showed ...

Zanubrutinib shows superior progression-free survival in chronic lymphocytic leukemia compared with acalabrutinib plus venetoclax, according to recent analysis. A matching-adjusted indirect comparison ...

Combination therapies for chronic lymphocytic leukemia (CLL) offer improved depth of response and potentially longer survival times compared with single-agent treatments. They target different ...